MARA Rating Insight 

Since 2020, assets averaging a 3.1 Cost-Effectiveness score sailed through HTA evaluations, while those at just 1.96 were far more likely rejected. That 1.14-point gap often determines whether payers call your price “reasonable” or “unaffordable.” MARA Scoring Framework …

Did you know? 

At MARA Rating, we harmonize the economic criteria of NICE (UK), G-BA/IQWiG (Germany) and ICER (US) into a simple A++ to C score—covering 350+ assets. Cost-Effectiveness shows whether payers will view your price as fair for the health gains you deliver.

What Is Cost-Effectiveness? 

It’s the economic analysis payers rely on to link costs with patient benefit:

• Incremental Costs: The net added expense of your therapy versus standard of care.
• Incremental Benefits (QALYs): The extra quality-adjusted life years your drug provides.
• Cost–Utility Analysis: The ICER compared against willingness-to-pay thresholds.
• Robustness of ICER Estimates: Sensitivity of results to model assumptions and data uncertainty.
• Transparency & Validity of Cost Inputs: Use of real-world costs and avoidance of hidden assumptions.
• Economic Model Reliability: Peer-reviewed structure, validation and credibility of your cost-effectiveness model. MARA Scoring Framework …

Strong vs. Marginal Scores

• A++ / A+ / A (“Strong or above”): These assets averaged ≥3.1 in Cost-Effectiveness—payers see clear value, face minimal pushback and often welcome premium pricing.
• B++ to C (“Marginal or below”): Assets at ≤1.96 faced steeper negotiations, price cuts and, in many cases, outright rejection.

Even a single-grade uplift can shift your dossier from “questionable investment” to “cost-justified.”

Actionable Tips by Role

• Market Access Professionals: Engage early with health-economic modelers—build robust, transparent ICER analyses into your dossiers and stress-test with sensitivity scenarios.
• Venture Investors & Acquirers: Vet assets with well-validated cost-utility models against local HTA thresholds—strong economic cases protect returns.
• Drug Developers: Source real-world cost data and document model assumptions clearly—demonstrate the reliability and relevance of your economic inputs to avert hidden-cost concerns.

See Your Edge Our anonymized score distributions across 350+ assets pinpoint where your economic case excels—and where it may falter in HTA review.

Do you know how your product scores? Visit mararating.com or send us a line.

#MarketAccess #HTA #EvidenceStrategy #CostEffectiveness #MARARating #MarketAccessScore